Mayo Comprehensive Cancer Center Grant (MICEO Supp) - Impact of Multi-Channel Communication Campaigns on Cancer Prevention, Control and Survivorship (CaPCaS) in Black, Hispanic, and Rural Populations

梅奥综合癌症中心拨款 (MICEO Supp) - 多渠道沟通活动对黑人、西班牙裔和农村人口癌症预防、控制和生存 (CaPCaS) 的影响

• 批准号: 10889628
• 负责人: CHERYL LYNN WILLMAN
• 金额: $ 20万
• 依托单位: MAYO CLINIC ROCHESTER
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-09-01 至 2024-02-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10889628
• 关键词: Administrative Supplement; Adoption; Advocate; Arizona; Attitude; Awareness; Behavior; Behavioral; Black Populations; Breast; Cancer Advocacy; Cancer Center Support Grant; Cancer Death Rates; Catchment Area; Clinic; Clinical Trials; Colorectal; Colorectal Cancer; Communication; Communities; Community Health; Community Outreach; Comprehensive Cancer Center; Continuity of Patient Care; Death Rate; Education; Florida; General Population; Geography; Goals; Grant; Health; Health Educators; Health Professional; Health system; Hispanic; Hispanic Populations; Intention; Knowledge; Life Style; Lung; Malignant Neoplasms; Malignant neoplasm of liver; Malignant neoplasm of lung; Malignant neoplasm of prostate; Midwestern United States; Pancreas; Population; Prevention; Preventive; Prostate; Public Health; Research Personnel; Rural Population; Scientist; Site; Survivors; Target Populations; Training; aged; black men; cancer care; cancer health disparity; cancer prevention; community engagement; evidence base; genetic testing; handbook; health communication; health equity; implementation science; improved; innovation; literacy; mortality; programs; response; screening; survivorship

ABSTRACT This application is being submitted by the Mayo Clinic Comprehensive Cancer Center (MCCCC) in response to the “Administrative Supplements for the NCI P30 Cancer Center Support Grants for Multi-Channel Communication Campaigns”. The MCCCC community outreach and engagement activities are led by the MCCCC Community Outreach & Engagement (COE) Office and Programs in three MCCCC catchment areas (CAs), including Arizona (AZ), Florida (FL) and the Midwest/Mayo Clinic Health Systems (MCHS). Although our 3-site catchment areas (CAs) are unique communities, the top cancers at each site are lung, breast, prostate, colorectal and pancreas. However, cancer disparities are uniquely different for the priority populations. In AZ CA, the targeted cancers are colorectal cancer (CRC) and liver cancer. Hispanics are twice likely to die from liver cancer compared to NH Whites. Although the CRC mortality rate is similar for both Hispanic and NH Whites, the CRC mortality rate for AZ CA Hispanics is elevated compared to US Hispanics. In FL CA, the targeted cancer is prostate cancer (CaP) in NH Black men. CaP leads cancer mortality among NH Blacks in the FL CA. Black men are twice as likely to die from CaP. The CaP death rate for Black men in FL is also elevated compared to the death rate for US Black men. In the Midwest/MCHS CA, the targeted cancers are lung, prostate, and colorectal cancers. These cancers are three of the top five cancers in the CA. The proposed supplement project focuses on Track 2, targeting the general population aged 30 years and above. Multi-channel communication campaigns will be delivered by Community Health Educators (CHEs) across the cancer care continuum and tailored to each of the MCCCC CAs. The primary goal of the supplement is to assess the impact of multi-channel communication campaigns targeting Black, Hispanic, and Rural populations on cancer prevention, control and survivorship (CaPCaS). This goal will be achieved through three specific aims: (1) Using the MCCCC Cancer Advocacy Handbook, train 15 (5 at each site) cancer advocates/survivors to lead the CaPCaS communication campaigns as CHEs, focusing primarily on improving cancer health and clinical trials literacy, increasing awareness about cancer prevention, screenings and genetic testing, and promoting preventive lifestyle behaviors; Adapt and implement evidence-based and innovative, culturally tailored, multi-channel educational communication campaigns tailored to Black men in FL CA, Hispanics in AZ CA and rural populations in the Midwest/MCHS geographies; and Evaluate the impact of the CaPCaS campaigns relative to increasing CaPCaS-related knowledge, attitudes, behavioral intention and adoption of prevention behavior.The academic-community team assembled for this project is comprised of health equity scientists, behavioral scientists (including implementation science researchers), clinician scientists, and public health professionals with significant expertise in health communications. (2) (3)

抽象的 该申请由梅奥诊所综合癌症中心 (MCCCC) 提交 对“NCI P30 癌症中心多渠道支持补助金的行政补充”的回应 MCCCC 社区外展和参与活动由 MCCCC 社区外展与参与 (COE) 办公室和位于三个 MCCCC 流域的项目 （CA），包括亚利桑那州（AZ）、佛罗里达州（FL）和中西部/梅奥诊所卫生系统（MCHS）。 3 个站点的集水区 (CA) 是独特的社区，每个站点的顶级癌症是肺癌、乳腺癌、前列腺癌、 然而，在 AZ 的优先人群中，结直肠癌和胰腺癌的差异是独特的。 CA，目标癌症是结直肠癌（CRC）和肝癌，西班牙裔人死于癌症的可能性是其两倍。 与新罕布什尔州白人相比，肝癌虽然西班牙裔和新罕布什尔州白人的结直肠癌死亡率相似， 与美国佛罗里达州西班牙裔人群相比，亚利桑那州加利福尼亚州西班牙裔人群的结直肠癌死亡率较高。 新罕布什尔州黑人中的前列腺癌 (CaP) 导致佛罗里达州新罕布什尔州黑人的癌症死亡率。 男性死于 CapP 的可能性是佛罗里达州黑人男性的 CapP 死亡率也高于男性。 美国黑人男性的死亡率 在中西部/MCHS CA，目标癌症是肺癌、前列腺癌和癌症。 这些癌症是加州最常见的五种癌症中的三种。 拟议的补充项目侧重于轨道2，针对30岁的一般人群 多渠道沟通活动将由社区健康教育者 (CHE) 开展。 涵盖整个癌症护理连续体，并针对每个 MCCCC CA 进行定制 该补充剂的主要目标。 旨在评估针对黑人、西班牙裔和农村地区的多渠道沟通活动的影响 人口癌症预防、控制和生存（CaPCaS）这一目标将通过三个目标来实现。 具体目标： (1) 使用 MCCCC 癌症宣传手册，培训 15 种（每个地点 5 种）癌症 倡导者/幸存者作为 CHE 领导 CaPCaS 沟通活动，主要侧重于改进 癌症健康和临床试验素养，提高对癌症预防、筛查和遗传的认识 测试并促进预防性生活方式行为；适应和实施基于证据的创新性的、 为佛罗里达州黑人男性量身定制的文化定制、多渠道教育传播活动， 亚利桑那州、加利福尼亚州的西班牙裔人口和中西部/MCHS 地区的农村人口；并评估该事件的影响； CaPCaS 活动涉及增加与 CaPCaS 相关的知识、态度、行为意图和 采用预防行为。为该项目组建的学术界团队由健康 公平科学家、行为公平科学家（包括实施科学研究人员）、临床科学家，以及 在健康传播方面拥有丰富专业知识的公共卫生专业人员。 (2) (3)

项目成果

Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer.

卵巢癌女性中 BRIP1、BARD1、PALB2 和 NBN 基因的种系突变。

• DOI: 10.1093/jnci/djv214
• 发表时间: 2015-11-01
• 期刊: Journal of the National Cancer Institute
• 作者: S. Ramus;Honglin Song;E. Dicks;J. Tyrer;A. Rosenthal;M. Intermaggio;L. Fraser;A. Gentry;J. Hayward;S. Philpott;C. Anderson;C. Edlund;D. Conti;P. Harrington;D. Barrowdale;D. Bowtell;K. Alsop;G. Mitchell;M. Cicek;J. Cunningham;B. Fridley;J. Alsop;M. Jimenez;S. Poblete;S. Lele;Lara E Sucheston;K. Moysich;W. Sieh;V. McGuire;J. Lester;N. Bogdanova;M. Dürst;P. Hillemanns;K. Odunsi;A. Whittemore;B. Karlan;T. Dörk;E. Goode;U. Menon;I. Jacobs;A. Antoniou;P. Pharoah;S. Gayther
• 通讯作者: S. Gayther

Regulation of Tumor Dendritic Cells by Programmed Cell Death 1 Pathways.

程序性细胞死亡 1 途径对肿瘤树突细胞的调节。

• DOI: 10.4049/jimmunol.2300674
• 发表时间: 2024-05-01
• 期刊: Journal of immunology
• 影响因子: 4.4
• 作者: Keith L Knutson

Evaluation of Sensitivity to Endocrine Therapy Index (SET2,3) for Response to Neoadjuvant Endocrine Therapy and Longer-Term Breast Cancer Patient Outcomes (Alliance Z1031).

评估内分泌治疗指数 (SET2,3) 的敏感性，以评估新辅助内分泌治疗的反应和乳腺癌患者的长期结果 (Alliance Z1031)。

• 发表时间: 2022-08-02
• 作者: Suman, Vera J;Du, Lili;Hoskin, Tanya;Anurag, Meenakshi;Ma, Cynthia;Bedrosian, Isabelle;Hunt, Kelly K;Ellis, Matthew J;Symmans, W Fraser
• 通讯作者: Symmans, W Fraser

Phase I/randomized phase II trial of TRC105 plus bevacizumab versus bevacizumab in recurrent glioblastoma: North Central Cancer Treatment Group N1174 (Alliance).

TRC105 加贝伐单抗与贝伐单抗治疗复发性胶质母细胞瘤的 I 期/随机 II 期试验：北中心癌症治疗组 N1174（联盟）。

• 发表时间: 2022
• 作者: Galanis, Evanthia;Anderson, S Keith;Twohy, Erin;Butowski, Nicholas A;Hormigo, Adilia;Schiff, David;Omuro, Antonio;Jaeckle, Kurt A;Kumar, Shaji;Kaufmann, Timothy J;Geyer, Susan;Kumthekar, Priya U;Campian, Jian;Giannini, Caterina;Buckner, Jan
• 通讯作者: Buckner, Jan

Towards defining morphologic parameters of normal parous and nulliparous breast tissues by artificial intelligence.

通过人工智能定义正常经产和未产乳腺组织的形态参数。

• 发表时间: 2022-07-11
• 作者: Ogony, Joshua;de Bel, Thomas;Radisky, Derek C;Kachergus, Jennifer;Thompson, E Aubrey;Degnim, Amy C;Ruddy, Kathryn J;Hilton, Tracy;Stallings;Vachon, Celine;Hoskin, Tanya L;Heckman, Michael G;Vierkant, Robert A;White, Launia J;Moo
• 通讯作者: Moo